LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.93% for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-11-30 was 5.03%.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-11-30 was 1.66%, a 42.56% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-11-30 was 2.89%.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 0.78%, a 85.71% increase from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.42%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-05-31 | 3.93% 10-Q · filed 2026-07-13 | |||
| 2024-02-29 | 5.03% 10-Q · filed 2024-04-09 | |||
| 2023-11-30 | 5.03% 10-Q · filed 2024-01-12 | |||
| 2023-05-31 | 3.30% 10-Q · filed 2023-07-14 | |||
| 2023-02-28 | 0.75% 10-Q · filed 2023-04-14 | |||
| 2022-08-31 | 0.78% 10-K · filed 2022-11-28 | |||
| 2022-05-31 | 0.85% 10-Q · filed 2022-07-14 | |||
| 2021-08-31 | 0.42% 10-K · filed 2022-11-28 | |||
| 2021-05-31 | 0.85% 10-Q · filed 2021-07-15 | |||
| 2021-02-28 | 0.42% 10-Q · filed 2021-04-14 | |||
| 2019-11-30 | 1.66% 10-Q · filed 2020-01-09 | |||
| 2019-02-28 | 2.89% 10-Q · filed 2019-04-15 | |||
| 2018-11-30 | 2.89% 10-Q · filed 2019-01-11 | |||
| 2018-02-28 | 2.13% 10-Q · filed 2018-04-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |